Peptide guide

A structural index of the 23 research compounds in the catalogue, arranged by chain length and modification. Each entry gives identity and format and links to its product page and lot record.

NOTICE

Not for human consumption. Research purposes only.

Research areas map

NOTICE

Not for human consumption. Research purposes only. The map shows areas of published laboratory research for each compound; it is not a statement of any effect, use or suitability.

DSIP · Semax · Pinealon · Epithalon
GHRP-2 · GHRP-6 · Hexarelin · Ipamorelin · CJC-1295 with DAC · CJC-1295 no DAC (Mod GRF 1–29)
GHK-Cu · KPV · LL-37
Thymosin α1 · Thymalin · LL-37
SS-31 · MOTS-c
GLP-3 · AOD-9604 · MOTS-c
BPC-157 · KPV
TB-500 · BPC-157 · BPC-157 + TB-500 blend
FOXO4-DRI · Epithalon

Select a number or a label to highlight its compounds. A compound can appear in more than one area.

Index by structure

Peptide fragments03AOD-9604, BPC-157, TB-500
Short-chain peptides10DSIP, Epithalon, GHRP-2, GHRP-6, Hexarelin, Ipamorelin, KPV, Pinealon, Semax, SS-31
Long-chain peptides06CJC-1295 with DAC, CJC-1295 no DAC (Mod GRF 1–29), GLP-3, LL-37, MOTS-c, Thymosin α1
Copper complexes01GHK-Cu
Modified peptides & blends03BPC-157 + TB-500 blend, FOXO4-DRI, Thymalin

Peptide fragments

Synthetic sequences that reproduce a defined section of a longer parent protein.

AOD-9604	16-residue synthetic fragment based on hGH residues 177–191 with N-terminal Tyr Lyophilised powder, 5 mg/vial · PRODUCT PAGE
BPC-157	Pentadecapeptide, C62H98N16O22, MW 1419.5 Lyophilised powder, 5 mg/vial · PRODUCT PAGE
TB-500	Synthetic thymosin β4-derived peptide (Ac-LKKTETQ active-site fragment) Lyophilised powder, 10 mg/vial · PRODUCT PAGE

AOD-9604

16-residue synthetic fragment based on hGH residues 177–191 with N-terminal Tyr

Lyophilised powder, 5 mg/vial · PRODUCT PAGE

BPC-157

Pentadecapeptide, C62H98N16O22, MW 1419.5

Lyophilised powder, 5 mg/vial · PRODUCT PAGE

TB-500

Synthetic thymosin β4-derived peptide (Ac-LKKTETQ active-site fragment)

Lyophilised powder, 10 mg/vial · PRODUCT PAGE

Short-chain peptides

Sequences of roughly two to ten residues, several with D-amino acids or non-proteinogenic residues.

DSIP	Nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu Lyophilised powder, 10 mg/vial · PRODUCT PAGE
Epithalon	Tetrapeptide Ala-Glu-Asp-Gly Lyophilised powder, 10 mg/vial · PRODUCT PAGE
GHRP-2	Hexapeptide D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2 (pralmorelin) Lyophilised powder, 5 mg/vial · PRODUCT PAGE
GHRP-6	Hexapeptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 Lyophilised powder, 5 mg/vial · PRODUCT PAGE
Hexarelin	Hexapeptide His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2 (examorelin) Lyophilised powder, 5 mg/vial · PRODUCT PAGE
Ipamorelin	Pentapeptide Aib-His-D-2Nal-D-Phe-Lys-NH2 Lyophilised powder, 5 mg/vial · PRODUCT PAGE
KPV	Tripeptide Lys-Pro-Val, C-terminal fragment of α-MSH Lyophilised powder, 5 mg/vial · PRODUCT PAGE
Pinealon	Tripeptide Glu-Asp-Arg Lyophilised powder, 10 mg/vial · PRODUCT PAGE
Semax	Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (ACTH 4–7 analogue with Pro-Gly-Pro) Lyophilised powder, 10 mg/vial · PRODUCT PAGE
SS-31	Tetrapeptide D-Arg-Dmt-Lys-Phe-NH2 (elamipretide) Lyophilised powder, 50 mg/vial · PRODUCT PAGE

Long-chain peptides

Sequences of more than ten residues, including acylated and conjugated analogues.

CJC-1295 no DAC (Mod GRF 1–29)	Tetra-substituted GRF(1–29) analogue, 29 residues, C-terminal amide Lyophilised powder, 5 mg/vial · PRODUCT PAGE
CJC-1295 with DAC	Tetra-substituted GRF(1–29) analogue with C-terminal Lys(maleimidopropionyl) — drug affinity complex (DAC) Lyophilised powder, 5 mg/vial · PRODUCT PAGE
GLP-3	Synthetic 39-residue acylated peptide LY3437943 (retatrutide); class: GIP / GLP-1 / glucagon receptor triple agonist; investigational compound Lyophilised powder, 10 mg/vial · PRODUCT PAGE
LL-37	37-residue cathelicidin-derived peptide (C-terminal domain of hCAP-18) Lyophilised powder, 5 mg/vial · PRODUCT PAGE
MOTS-c	16-residue mitochondrial-encoded peptide Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg Lyophilised powder, 10 mg/vial · PRODUCT PAGE
Thymosin α1	28-residue N-terminally acetylated peptide (thymosin α1) Lyophilised powder, 5 mg/vial · PRODUCT PAGE

Copper complexes

Peptides supplied as a coordination complex with a copper(II) ion.

GHK-Cu	Copper tripeptide complex (Gly-His-Lys:Cu) Lyophilised powder, 50 mg/vial · PRODUCT PAGE

GHK-Cu

Copper tripeptide complex (Gly-His-Lys:Cu)

Lyophilised powder, 50 mg/vial · PRODUCT PAGE

Modified peptides & blends

Retro-inverso constructs, polypeptide complexes and two-component vials.

BPC-157 + TB-500 blend	Two-component vial: BPC-157 5 mg and TB-500 5 mg Lyophilised powder, 5 mg / 5 mg/vial · PRODUCT PAGE
FOXO4-DRI	D-retro-inverso peptide based on a FOXO4 sequence with a TAT cell-penetrating motif Lyophilised powder, 10 mg/vial · PRODUCT PAGE
Thymalin	Thymus-derived polypeptide complex, lyophilised Lyophilised powder, 20 mg/vial · PRODUCT PAGE

BPC-157 + TB-500 blend

Two-component vial: BPC-157 5 mg and TB-500 5 mg

Lyophilised powder, 5 mg / 5 mg/vial · PRODUCT PAGE

FOXO4-DRI

D-retro-inverso peptide based on a FOXO4 sequence with a TAT cell-penetrating motif

Lyophilised powder, 10 mg/vial · PRODUCT PAGE

Thymalin

Thymus-derived polypeptide complex, lyophilised

Lyophilised powder, 20 mg/vial · PRODUCT PAGE

Reading an entry

IDENTITY	Structural description: residue count, sequence in three-letter code where it is short, and notable modifications such as D-residues, C-terminal amidation, acylation or metal coordination.
FORMAT	Physical form and nominal net content per vial, as listed on the product page.
PURITY	Not shown here. Purity and identity are reported per lot (HPLC and ESI-MS) on the certificate of analysis; the COA for each lot is authoritative.

Storage & handling

STORAGE	Store lyophilised at −20 °C, protected from light and moisture.
HANDLING	For qualified personnel in a suitably equipped laboratory, using appropriate protective equipment.
RECORDS	Each vial carries a lot number. LOOK UP A LOT